These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 11195537)

  • 21. Enhancement of the response to levodopa therapy after intrastriatal transplantation of autologous sympathetic neurons in patients with Parkinson disease.
    Nakao N; Kakishita K; Uematsu Y; Yoshimasu T; Bessho T; Nakai K; Naito Y; Itakura T
    J Neurosurg; 2001 Aug; 95(2):275-84. PubMed ID: 11780898
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Daily motor performance after switching levodopa to melevodopa: an open-label on advanced Parkinson's disease with "delayed-on" and/or"wearing-off".
    Bosco D; Plastino M; Bosco F; Fava A; Rotondo A
    Minerva Med; 2011 Apr; 102(2):125-32. PubMed ID: 21483399
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical analysis of the efficiency of the pathogenetic therapy for patients with parkinsonism].
    Karaban' NV
    Lik Sprava; 2007; (1-2):61-5. PubMed ID: 17684804
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dihydroergocryptine in the management of senile psycho-organic syndrome.
    Scarzella L; Bono G; Bergamasco B
    Int J Clin Pharmacol Res; 1992; 12(1):37-46. PubMed ID: 1526697
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Study of the therapeutic action of Vasobral in ORL pathology].
    Pech A; Cannoni M; Zanaret M
    J Fr Otorhinolaryngol Audiophonol Chir Maxillofac; 1984 Mar; 33(3):149-52. PubMed ID: 6425452
    [No Abstract]   [Full Text] [Related]  

  • 26. Effect of controlled-release carbidopa/levodopa on motor performance in advanced Parkinson's disease.
    Rondot P; Ziegler M; Aymard N; Teinturier A
    Neurology; 1989 Nov; 39(11 Suppl 2):74-7; discussion 95. PubMed ID: 2586765
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cognitive dysfunction in early onset parkinsonism.
    Tsai CH; Lu CS; Hua MS; Lo WL; Lo SK
    Acta Neurol Scand; 1994 Jan; 89(1):9-14. PubMed ID: 8178636
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anhedonia, depression, and motor functioning in Parkinson's disease during treatment with pramipexole.
    Lemke MR; Brecht HM; Koester J; Kraus PH; Reichmann H
    J Neuropsychiatry Clin Neurosci; 2005; 17(2):214-20. PubMed ID: 15939976
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Caffeine reversal of ethanol effects on the multiple sleep latency test, memory, and psychomotor performance.
    Drake CL; Roehrs T; Turner L; Scofield HM; Roth T
    Neuropsychopharmacology; 2003 Feb; 28(2):371-8. PubMed ID: 12589390
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
    Nyholm D; Nilsson Remahl AI; Dizdar N; Constantinescu R; Holmberg B; Jansson R; Aquilonius SM; Askmark H
    Neurology; 2005 Jan; 64(2):216-23. PubMed ID: 15668416
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of levodopa on cognitive functioning in moderate-to-severe Parkinson's disease (MSPD).
    Morrison CE; Borod JC; Brin MF; Hälbig TD; Olanow CW
    J Neural Transm (Vienna); 2004 Oct; 111(10-11):1333-41. PubMed ID: 15480842
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Experience with amysil treatment of patients with vascular parkinsonism].
    Kamenetskiĭ VK
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1989; 89(9):56-9. PubMed ID: 2692361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safinamide in the treatment of Parkinson's disease.
    Schapira AH
    Expert Opin Pharmacother; 2010 Sep; 11(13):2261-8. PubMed ID: 20707760
    [TBL] [Abstract][Full Text] [Related]  

  • 34. fMRI changes in cortical activation during task performance with the unaffected hand partially reverse after ropinirole treatment in de novo Parkinson's disease.
    Tessa C; Diciotti S; Lucetti C; Baldacci F; Cecchi P; Giannelli M; Bonuccelli U; Mascalchi M
    Parkinsonism Relat Disord; 2013 Feb; 19(2):265-8. PubMed ID: 22901957
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Psychophysiological approach in Parkinson's disease: L-dopa effects on preprogramming and control activity.
    Fattapposta F; Pierelli F; My F; Mostarda M; Del Monte S; Parisi L; Serrao M; Locuratolo N; Amabile G
    Neurol Sci; 2002 Sep; 23 Suppl 2():S73-4. PubMed ID: 12548350
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Action naming in Parkinson's disease patients on/off dopamine.
    Herrera E; Cuetos F
    Neurosci Lett; 2012 Apr; 513(2):219-22. PubMed ID: 22387157
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of Parkinson's disease and dopaminergic medication on adaptation to explicit and implicit visuomotor perturbations.
    Mongeon D; Blanchet P; Messier J
    Brain Cogn; 2013 Mar; 81(2):271-82. PubMed ID: 23313834
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Finasteride attenuates pathological gambling in patients with Parkinson disease.
    Bortolato M; Cannas A; Solla P; Bini V; Puligheddu M; Marrosu F
    J Clin Psychopharmacol; 2012 Jun; 32(3):424-5. PubMed ID: 22534502
    [No Abstract]   [Full Text] [Related]  

  • 39. Inter-patient and intra-patient variations in the baseline tapping test in patients with Parkinson's disease.
    Wu G; Baraldo M; Furlanut M
    Acta Neurol Belg; 1999 Sep; 99(3):182-4. PubMed ID: 10544726
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Continuous dopaminergic stimulation in Parkinson disease: possibilities in 2013].
    Aschermann Z; Kovács N; Komoly S
    Ideggyogy Sz; 2013 May; 66(5-6):209-10. PubMed ID: 23909024
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.